New composition of matter claims establish intellectual property for Enveric's EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ:…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
New composition of matter claims expands intellectual property for Enveric's EVM201 Series CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
Research highlights the potential of Enveric's EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposure CAMBRIDGE, Mass.…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
Intellectual property describes composition of matter claims governing Enveric's lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ:…
Read More
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for…
Read More
Enveric is advancing EB-373, a psilocin prodrug for anxiety disorders and its EVM301 Series of novel non-hallucinatory brain plastogens to treat mental health disorders. CAMBRIDGE, Mass. - Enveric Biosciences, Inc.…
Read More
CEO Joseph Tucker, Ph.D., to discuss Enveric's pipeline and therapeutic opportunities in fireside chat and "NextGen Psychedelics" panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),…
Read More
Key Highlights Nominated EB-373 as lead development candidate for the treatment of anxiety disorders EB-373 is a next generation proprietary psilocin prodrug selected from Enveric's EVM201 Series and developed leveraging…
Read More
